MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.rpth.2026.106870

Медицинская библиотека · Research and practice in thrombosis and haemostasis · 2026

Prospective collection of bleeding rate and factor usage in participants with hemophilia A and B in a noninvestigational product study.

Kavakli Kaan, Frenzel Laurent, Antmen Ali Bulent, Alzahrani Hazzaa, Matino Davide, Leavitt Andrew D, Ozelo Margareth C, Astermark Jan, Park Young-Shil, Klamroth Robert, Cuker Adam, Konkle Barbara A, McKay John, Agathon Delphine, Tseng Li-Jung, Resa Maria de Los Angeles, Healy Jasmine, Wilcox Lisa J, Plonski Frank

СтатьяМногоцентровое исследованиеКлиническое исследованиеПеревод в очереди

Аннотация

BACKGROUND

We report efficacy and select safety outcomes of current factor prophylaxis of adults with moderately severe to severe hemophilia A (HA) or hemophilia B (HB) in a large, prospective, noninvestigational product study.

OBJECTIVES

This study established prospective efficacy data on factor (F)VIII/FIX prophylaxis in the usual care setting.

METHODS

This prospective, open-label, noninvestigational product, multicenter study (BENEGENE-1) included HA and HB cohorts. Participants remained on their current factor replacement therapy. The primary end point was annualized bleeding rate. Secondary end points included annualized infusion rate of FVIII/FIX replacement therapy. Safety data were also collected.

RESULTS

In total, 241 individuals with HA and 333 with HB were screened, and 101 and 111, respectively, were enrolled in this study. The most common reason for screen failure was adeno-associated virus neutralizing antibody positivity, accounting for 82.1% and 92.3% of screen failures in the HA and HB cohorts, respectively. The corresponding overall mean (SD; range) follow-up duration was 310.8 (209.2; 14-948) and 498.6 (293.4; 117-1269) days. Mean (SD) total annualized bleeding rate and annualized infusion rate were 6.1 (10.6) and 127.1 (51.8) for participants with HA and 4.5 (9.4) and 62.8 (33.3) for participants with HB, respectively. No new safety concerns were identified with FVIII/FIX replacement therapy.

CONCLUSION

This study provides a robust, prospective, informative dataset on bleeding rates in participants receiving factor replacement therapy over a mean follow-up of ∼1 year. Although FVIII/FIX prophylaxis was generally well tolerated, bleeding rate data illustrate the limitations of current standard-of-care factor prophylaxis.

Для цитирования: Kavakli Kaan, Frenzel Laurent, Antmen Ali Bulent, Alzahrani Hazzaa, Matino Davide, Leavitt Andrew D, Ozelo Margareth C, Astermark Jan, Park Young-Shil, Klamroth Robert, Cuker Adam, Konkle Barbara A, McKay John, Agathon Delphine, Tseng Li-Jung, Resa Maria de Los Angeles, Healy Jasmine, Wilcox Lisa J, Plonski Frank. Prospective collection of bleeding rate and factor usage in participants with hemophilia A and B in a noninvestigational product study.. Research and practice in thrombosis and haemostasis. 2026. DOI: 10.1016/j.rpth.2026.106870.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.